Lead Product(s) : Senicapoc
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Researchers IN Denmark Testing if Senicapoc Drug Can Reduce Lung Damage In Covid-19 Patients
Details : The Danish government has given a grant to a research team at Aarhus University to launch a clinical trial which will investigate if the treatment can prevent the lung damage seen in COVID-19 and SARS, to reduce the need for a patient to be on a ventilat...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 13, 2020
Lead Product(s) : Senicapoc
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?